{"schema_version":"secwatch.filing_event.v1","accession":"0001827090-25-000034","form_type":"8-K","ticker":"CERT","cik":"0001827090","company_name":"Certara, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.173554+00:00","generated_at":"2026-05-17T19:52:45.909034+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Certara Q2 2025 revenue $104.6M (+12% YoY); net loss narrows to $2.0M; reiterates FY guidance","bullets":["Revenue $104.6M (+12% YoY); software revenue $46.7M (+22%), services $57.9M (+5%).","Net loss improved 84% to $2.0M from $12.6M in Q2 2024.","Adjusted EBITDA $31.9M (+21% YoY); Chemaxon contributed $5.3M to revenue.","Full-year 2025 financial guidance reaffirmed, citing sustained demand for model-informed drug development.","CEO highlighted software product enhancements and new product introductions driving long-term growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001827090-25-000034","json":"https://secwatch.observer/filing/0001827090-25-000034.json","markdown":"https://secwatch.observer/filing/0001827090-25-000034.md","text":"https://secwatch.observer/filing/0001827090-25-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1827090/000182709025000034/0001827090-25-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1827090/000182709025000034/certara-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:52:45.909034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}